Gilead Sciences reported third-quarter product sales of $8.3 billion, a 13% increase year-over-year, driven by strong HIV and oncology performance. Diluted GAAP earnings per share were $1.94, while non-GAAP diluted EPS rose to $2.55 from $2.47 in the prior year period. The company raised its full-year 2026 product sales guidance range to $31.0–$31.3 billion, reflecting a total increase of $1.6 billion since the start of the year. Additionally, Gilead announced an updated quarterly dividend of $0.82 per share for Q4 2026. The company is a biopharmaceutical firm focused on HIV, viral hepatitis, oncology, and inflammation treatments.
